By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Viamet Pharmaceuticals 

406 Blackwell Street
Suite 200
Durham  North Carolina  27701-3984  U.S.A.
Phone: 919-969-7505 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
Viamet To Provide Update On Novel Antifungal Programs At ECCMID 2015 4/24/2015 7:32:34 AM
Led By Ex-Elan (ELN) Execs, Malin Rakes in $350 Million and Looks to Invest in Viamet, Novan Therapeutics 3/25/2015 6:27:34 AM
Viamet Pharmaceuticals Announces Initiation Of RENOVATE Phase 2b Study Of Oral VT-1161 In Onychomycosis 3/10/2015 10:50:13 AM
Viamet Pharmaceuticals Announces Initiation Of REVIVE Phase 2b Study Of VT-1161 In Recurrent Vulvovaginal Candidiasis 2/12/2015 8:32:53 AM
Viamet Pharmaceuticals Withdraws $75 Million IPO, Spins Off Cancer Program To Form Innocrin Pharmaceuticals 10/22/2014 6:15:45 AM
Viamet Pharmaceuticals Reels In $60 Million Series D Financing 10/21/2014 5:38:42 AM
Viamet Pharmaceuticals Receives Orphan Drug Designation For VT-1129 9/11/2014 10:11:08 AM
Viamet Pharmaceuticals Announces Appointment Of Amir Tavakkol, Ph.D., As Chief Development Officer 7/22/2014 10:24:59 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014 11:04:25 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014 9:20:05 AM
123
//-->